Roche’s Immunotherapy Drug Tecentriq Extended Patients’ Lives in Study – Wall Street Journal
Wall Street Journal |
Roche's Immunotherapy Drug Tecentriq Extended Patients' Lives in Study
Wall Street Journal Roche Holding AG RHHBY 1.26% said Thursday that its immunotherapy drug Tecentriq slowed the progression of lung cancer and helped patients live longer in a late-stage study, offering a new hope for patients and bolstering the Swiss drugmaker's defense … |
